<https://bpno.no/medtalks/belzutifan-is-well-tolerated-and-might-be-an-addition-to-a-standard-of-care/>
<http://schema.org/description>
"Katriina Jalkanen, from Helsinki University Hospital, discusses the LITESPARK study results on belzutifan, a new drug for renal cell carcinoma (RCC), at ESMO 2024. Key findings include statistically significant progression-free survival (PFS) with belzutifan compared to everolimus and a higher response rate (22.7% vs. 3.5%). In addition belzutifan is well-tolerated and could be used in future treatment combinations or earlier lines an Addition to a Standard of Care."
<https://bpno.no/medtalks/belzutifan-is-well-tolerated-and-might-be-an-addition-to-a-standard-of-care/>